January 23, 2007
Product news from the 1/23/07 news brief
The FDA has approved Shire’s Lialda (mesalamine) indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Lialda is the first and only FDA-approved once-daily oral formulation of mesalamine. Shire will launch Lialda in the US during the first quarter of 2007.
Stiefel Laboratories received FDA approval for Olux-E (clobetasol propionate) foam, indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, also known as psoriasis and eczema, in patients 12 years of age or older. Steifel said Olux-E is will be available in U.S. pharmacies by March 2007 in 50 g and 100 g canisters.